Growth and differentiation factor-15: A link between inflammaging and cardiovascular disease

Nyárády, Balázs Bence; Kiss, Loretta Zsuzsa; Bagyura, Zsolt; Merkely, Béla; Dósa, Edit; Láng, Orsolya; Kőhidai, László; Pállinger, Éva

doi:10.1016/j.biopha.2024.116475

Cited by 2 publications

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In atherosclerosis, which is a chronic inflammatory condition characterized by the monocytes activity in lipid deposition within vessel walls [41]. These monocytes, upon ingestion of lipoproteins like oxLDLs, transform into macrophages and give rise to foam cells.…”

Section: Gdf-15mentioning

confidence: 99%

See 1 more Smart Citation

Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach

Fularski,

Czarnik,

Dąbek

et al. 2024

IJMS

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease (ASCVD) stands as the leading cause of mortality worldwide. At its core lies a progressive process of atherosclerosis, influenced by multiple factors. Among them, lifestyle-related factors are highlighted, with inadequate diet being one of the foremost, alongside factors such as cigarette smoking, low physical activity, and sleep deprivation. Another substantial group of risk factors comprises comorbidities. Amongst others, conditions such as hypertension, diabetes mellitus (DM), chronic kidney disease (CKD), or familial hypercholesterolemia (FH) are included here. Extremely significant in the context of halting progression is counteracting the mentioned risk factors, including through treatment of the underlying disease. What is more, in recent years, there has been increasing attention paid to perceiving atherosclerosis as an inflammation-related disease. Consequently, efforts are directed towards exploring new anti-inflammatory medications to limit ASCVD progression. Simultaneously, research is underway to identify biomarkers capable of providing insights into the ongoing process of atherosclerotic plaque formation. The aim of this study is to provide a broader perspective on ASCVD, particularly focusing on its characteristics, traditional and novel treatment methods, and biomarkers that can facilitate its early detection.

show abstract

Section: Gdf-15mentioning

confidence: 99%

“…By delineating the pathways through which these cells influence disease progression, research continues to unravel the potential for targeted interventions aimed at modulating immune cell activity in atherosclerosis [81]. The inflammatory cascade of markers has been shown at Figure 2 [41,50,80]. erogenic environment.…”

Section: Immune Cellsmentioning

confidence: 99%

Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach

Fularski,

Czarnik,

Dąbek

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways

de Lima,

Moretti,

Torres Pomini

et al. 2024

Biology

View full text Add to dashboard Cite

Glycolipid metabolic disorders (GLMDs) are various metabolic disorders resulting from dysregulation in glycolipid levels, consequently leading to an increased risk of obesity, diabetes, liver dysfunction, neuromuscular complications, and cardiorenal vascular diseases (CRVDs). In patients with GLMDs, excess caloric intake and a lack of physical activity may contribute to oxidative stress (OxS) and systemic inflammation. This study aimed to review the connection between GLMD, OxS, metainflammation, and the onset of CRVD. GLMD is due to various metabolic disorders causing dysfunction in the synthesis, breakdown, and absorption of glucose and lipids in the body, resulting in excessive ectopic accumulation of these molecules. This is mainly due to neuroendocrine dysregulation, insulin resistance, OxS, and metainflammation. In GLMD, many inflammatory markers and defense cells play a vital role in related tissues and organs, such as blood vessels, pancreatic islets, the liver, muscle, the kidneys, and adipocytes, promoting inflammatory lesions that affect various interconnected organs through their signaling pathways. Advanced glycation end products, ATP-binding cassette transporter 1, Glucagon-like peptide-1, Toll-like receptor-4, and sphingosine-1-phosphate (S1P) play a crucial role in GLMD since they are related to glucolipid metabolism. The consequences of this is system organ damage and increased morbidity and mortality.

show abstract

Growth and differentiation factor-15: A link between inflammaging and cardiovascular disease

Cited by 2 publications

References 74 publications

Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach

Broader Perspective on Atherosclerosis—Selected Risk Factors, Biomarkers, and Therapeutic Approach

Glycolipid Metabolic Disorders, Metainflammation, Oxidative Stress, and Cardiovascular Diseases: Unraveling Pathways

Contact Info

Product

Resources

About